Anjali S. Advani - Concepedia

Author

Anjali S. Advani

Also Known As

A Advani, A S Advani, A. Advani, A. S. Advani, A.S. Advani, Aarushi Advani, Advani A., Advani, Anjali S, Anjali S. Advani, Anjali Advani

620

Publications

13.5K

Citations

H-Index

Concepts

All Affiliations

Cleveland Clinic Dana-Farber Cancer Institute Fred Hutch Cancer Center The University of Texas MD Anderson Cancer Center University of Chicago

About

Anjali S. Advani is an author at Cleveland Clinic specializing in medicine, hematology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	28	52	3.5K
2	Health Sciences	20	29	1.9K
3	Public Health	2	2	84
4	Engineering	1	1	70
5	Social Sciences	1	1	15

Anjali S. Advani

147

Publications

11.5K

Citations

H-Index

Page 1

	Year	Citations
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia Hagop M. Kantarjian, Daniel J. DeAngelo, Matthias Stelljes, New England Journal of Medicine	2016	1.3K
A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403 Wendy Stock, Selina M. Luger, Anjali S. Advani, Blood	2019	454
Inotuzumab ozogamicin, an anti-CD22–calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study Hagop M. Kantarjian, Deborah A. Thomas, Jeffrey L. Jorgensen, The Lancet Oncology Inotuzumab OzogamicinLymphoid NeoplasiaHematological MalignancyMedicineAnti-cd22–calecheamicin Conjugate	2012	410
Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse Mark J. Levis, Farhad Ravandi, Eunice S. Wang, Blood	2011	395
Safety, Pharmacokinetics, and Preliminary Clinical Activity of Inotuzumab Ozogamicin, a Novel Immunoconjugate for the Treatment of B-Cell Non-Hodgkin's Lymphoma: Results of a Phase I Study Anjali S. Advani, Bertrand Coiffier, Myron S. Czuczman, Journal of Clinical Oncology Novel ImmunoconjugateImmunologyPharmacotherapyMetronomic ChemotherapyRefractory Cd22	2010	329
Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long‐term survival follow‐up from the randomized, phase 3 INO‐VATE study Hagop M. Kantarjian, Daniel J. DeAngelo, Matthias Stelljes, Cancer	2019	316
Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia Geoffrey L. Uy, Ibrahim Aldoss, Matthew C. Foster, Blood	2020	307
Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms Fabı́ola Traina, Valeria Visconte, Paul Elson, Leukemia Hematological MalignancyMolecular MutationsMedicineTreatment ResponseDnmt Inhibitors	2013	283
Acute Lymphoblastic Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology Patrick A. Brown, Bijal Shah, Anjali S. Advani, Journal of the National Comprehensive Cancer Network Hematological MalignancyNccn All PanelMedicinePhiladelphia ChromosomeMixed-phenotype Acute Leukemia	2021	230
Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel Wendy Stock, Dan Douer, Daniel J. DeAngelo, Leukemia & lymphoma/Leukemia and lymphoma	2011	228

Page 1